Clinical Trial Update: Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children [Phase 2]

View source ↗

Summary

Phase 2 study of long-acting growth hormone MOD-4023 in pediatric growth hormone deficiency completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Growth Hormone Deficiency

Drugs mentioned

• MOD-4023 (long-acting growth hormone)

Snippet

Sponsor: OPKO Health, Inc. | Conditions: Pediatric Growth Hormone Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2020-01-23